A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Hormone Receptor Positive Breast Cancer|HER-2 Positive Breast Cancer
Interventions: DRUG: Abemaciclib|DRUG: Trastuzumab|DRUG: Fulvestrant|DRUG: Standard of Care Single Agent Chemotherapy
Sponsor: Eli Lilly and Company